Literature DB >> 10570556

Schnitzler's syndrome: report of a case with progression to Waldenström's macroglobulinaemia.

B Welsh1, B Tate.   

Abstract

Schnitzler's syndrome is a rare but distinct entity in which chronic urticaria is a prominent feature. Our patient presented with an urticarial rash associated with intermittent fevers, lethargy, a migratory polyarthralgia and loss of weight. Skin biopsy revealed a neutrophilic urticaria. An IgM kappa paraprotein was detected on serum protein electrophoresis at a level of 8 g/L (0.6-2.5 g/L). Bone marrow biopsy was normal. Marked improvement of the arthralgia, fever and lethargy was obtained with oral prednisolone. The urticarial rash, however, was only partly responsive. For the next 10 years the patient remained stable but corticosteroid dependent. Over a period of 10 years the IgM paraprotein had slowly risen to 47 g/L. Repeat bone aspirate and trephine revealed a diagnosis of a low grade lymphoplasmacytic lymphoma consistent with Waldenström's macroglobulinaemia. To date, despite six cycles of chemotherapy with oral chlorambucil, his disease remains persistent but stable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570556     DOI: 10.1046/j.1440-0960.1999.00361.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  4 in total

Review 1.  Schnitzler Syndrome: a Review.

Authors:  L Gusdorf; D Lipsker
Journal:  Curr Rheumatol Rep       Date:  2017-08       Impact factor: 4.592

Review 2.  Autoinflammation: From monogenic syndromes to common skin diseases.

Authors:  Tien V Nguyen; Edward W Cowen; Kieron S Leslie
Journal:  J Am Acad Dermatol       Date:  2013-02-28       Impact factor: 11.527

Review 3.  The Schnitzler syndrome.

Authors:  Dan Lipsker
Journal:  Orphanet J Rare Dis       Date:  2010-12-08       Impact factor: 4.123

Review 4.  Schnitzler's syndrome: lessons from 281 cases.

Authors:  Heleen D de Koning
Journal:  Clin Transl Allergy       Date:  2014-12-05       Impact factor: 5.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.